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                                             ABSTRACT 
Pathogens are treated with antibiotics from years, bacterial pathogens are either resistant or 
sensitive to antibiotics. Regular administration of antibiotic to pathogen produces drug resistance 
strains. Most of the bacterial pathogen already acquires multi-drug resistance characteristics. 
Pseudomonas aeruginosa is resistance to almost all antibiotics for example; 
tetracycline,kanamycin, chloramphenicol , vancomycin etc..the MIC study of these antibiotics 
shows the concentration at which these pathogens can be inhibited. For pseudomonas, 
vancomycin MIC is 32  µg/ml, penicillin is 8 µg/ml, chloramphenicol 16 µg/ml. so also for 
proteus mirabilis vancomycin 16 µg/ml penicillin 4 µg/ml 
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INTRODUCTION:- 
A pathogen is a microorganism such as a virus, bacterium, prion or fungus that causes disease in 
its animal or plant host. Pathogenic bacteria causes bacterial infection. Some species of bacteria, 
such as Burkholderia cenocepacia, Pseudomonas aeruginosa,  and Mycobacterium avium, 
are opportunistic pathogens and cause disease mainly in people suffering from 
immunosuppression or cystic fibrosis. (Heise, 1982; Saiman, 2004).  
Potency: 
A hypothesis regarding pathogens states, the longer a pathogen can survive outside of the body, 
the more dangerous it is to a potential host. For example, the pox virus (Variola virus) also 
survive outside the host for 885 days. It is one of the deadliest pathogenic viruses, responsible for 
20-50% of deaths by infectious. The tuberculosis bacterium kills 1 of 5 people it infects, but has 
a life of only 244 days outside the host. However, research on the ability of pathogens to cause 
disease provides evidence from multiple and diverse species of the existence of pathogenicity or 
virulence factors, encoded within the pathogens' genetic material, that facilitate microbes to 
cause disease. In countries that having higher sanitation standards, pathogens cannot survive for 
as long outside of the human. This leads to increased rate of mutation in the pathogen which 
would make it less deadly. These mutations allow the pathogen to survive in the host for longer 
periods of time. 
 
Treatment  
Antibiotics used to combat bacterial infections can be classified as bactericidal which kill 
bacteria, or bacteriostatic which prevent bacterial growth. Different antibiotics inhibit distinct 
process in the pathogen which are different from that found in the host. For example, the 
antibiotics chloramphenicol and tetracycline inhibit the bacterial ribosome, but not the 
structurally-different eukaryotic ribosome, and so exhibit selective toxicity (Yonath and Bashan, 
2004). Other than treating human diseases, antibiotics are extensively used in farming practices 
for preventing crop infections and both these processes aid in rapid development of antibiotic 
resistance in bacterial populations. (Khachatourians, 1998). Infections can be minimized 
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by antiseptic measures such as sterilizing the skin before to piercing it with the needle and by 
proper care of indwelling catheters. Dental and surgical instruments are also sterilized to prevent 
infection by bacteria. Disinfectants are used to kill bacteria and other pathogens on surfaces to 
prevent contamination and further reduce the risk of infection. Most bacteria in food are 
sterilized by cooking to temperatures above 73 °C (163°F). 
SCIENTIFIC CLASSIFICATION:- 
 
                   Proteus mirabilis:                   Kingdom:  Bacteria 
                                                                   Phylum:     Proteobacteria 
                                                                   Class   :      Gamma proteobacteria 
                                                                   Order:       Enterobacteriales 
                                                                   Family:      Enterobacteriaceae 
                                                                  Genus:        Proteus 
                                                                  Species:      P. mirabilis 
             
           Pseudomonas aeruginosa:            Kingdom:   Bacteria 
                                                                  Phylum:     Proteobacteria 
                                                                    Class:       Gammaproteobacteria 
                                                                 Order:         Pseudomonadales 
                                                                  Family:      Pseudomonadaceae 
                                                                   Genus:      Pseudomonas 
                                                               Species:     P. aeruginosa 
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Pseudomonas  
Pathogenic members of this genera include P. aeruginosa, P. oryzihabitans, and P. 
plecoglossicida. P. aeruginosa founds in hospital environments and is a common problem in this 
environment since it is the second most common causative agent of nosocomial infections. This 
pathogenesis may in part be due to the metabolites secreted by P. aeruginosa. The bacterium 
possesses a wide range of secretion systems, which secrets numerous proteins relevant to the 
pathogenesis of clinical strains (Hardie et al. 2009). Like most bacteria genera the pseudomonas 
last lived hundreds of million years ago; although they were classified by humans at the end of 
the XIX century. Due to their widespread occurrence in water and in plant seeds such as dicots, 
the pseudomonads were observed early in the history of microbiology. The genus  Pseudomonas 
created for these organisms was defined in rather vague terms by W. Migula in 1894 and 1900 as 
a genus of  rod-shaped, Gram-negative and polar-flagella bacteria with some sporulating 
species, the statement was later proved incorrect and due to refractive granules of reserve 
materials. Despite the vague description, the type species, Pseudomonas aeruginosa proved the 
best descriptor. Additionally, the etymology of the name was not provided and first appeared in 
the Bergey's manual (=top authority in bacterial nomenclature) as Greek pseudes (false) and 
monas (a single unit), which can mean false unit, but there is also the possibility that Migula 
intended it as false Monas, a non flagellate protist. Subsequently, the term "monad" was used in 
the early history of microbiology to denote single-celled organisms. Soon afterwards, 
pseudomonas were isolated from many natural niches, and a large number of species names were 
originally assigned to the genus. New methods and the extent of approaches based on the studies 
of conservative macromolecules have reclassified many strains. Pseudomonas aeruginosa is a 
common bacterium which is able to cause disease in animals, including humans. It is found in 
water, soil, skin flora, and most man-made environments throughout the world. It thrives not 
only in normal atmospheres but also in hypoxic atmospheres, and has, thus, colonized many 
natural and artificial environments. It uses a wide range of organic material for food; in animals, 
the versatility enables the organism to infect damaged tissues or people with reduced immunity. 
The symptoms of such infections are generalized inflammation and septic. If such infection 
occurs in critical body organs, such as the lungs, the urinary tract, and kidneys, the results can be 
fatal (Balcht et al, 1994). Because it thrives on most surfaces, this bacterium is also found on and 
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in medical equipment, causing cross-infections in hospitals and clinics. It is implicated in hot-tub 
rash. It is also able to decompose hydrocarbons and has been used to break down tar balls and oil 
from oil spills (Balcht et al, 1994; Itah and Essien, 2005). 
IDENTIFICATION 
It is a Gram-negative, aerobic, rod-shaped bacterium with unipolar motility (Ryan and Ray, 
2004) An opportunistic human pathogen, P. aeruginosa is also an opportunistic pathogen of 
plants (Iglewski, 1996). P. aeruginosa is the type speciesof the genus Pseudomonas (Migula) 
(Anzai et al, 2000). P. aeruginosa secretes a variety of pigments, including pyoverdine (yellow-
green and fluorescent), pyocyanin (blue-green) and pyorubin (red-brown). King, Ward, and 
Raney developed Pseudomonas Agar P (King A medium) for enhancing pyocyanin and pyorubin 
production, and Pseudomonas Agar F (King B medium) for enhancing fluorescein production 
(King et al, 1954).  P. aeruginosa is often preliminarily identified by its pearl like appearance 
and grape-like or tortilla-like odor in vitro. Definitive clinical identification of P. aeruginosa 
moreover includes identifying the production of pyocyanin and fluorescein, as well as its ability 
to grow at 42°C. P. aeruginosa is capable of growth in diesel and jet fuel, where it is known as 
a hydrocarbon-using microorganism, causing microbial corrosion. It creates dark, gellish mats 
sometimes improperly called "algae" due to their appearance.  Although classified as an aerobic 
organism, P. aeruginosa is considered by many as a facultative anaerobe, as it is well adapted to 
proliferate in conditions of partial or total oxygen depletion. This organism can 
achieve anaerobic growth with nitrate as aterminal electron acceptor, and, in its absence, it is also 
able to ferment arginine by substrate-level phosphorylation ( Palmer et al, 2007; Vander et al, 
1984). Adaptation to anaerobic or microaerobic environments is necessary for certain lifestyles 
of P. aeruginosa, for example, during lung infection in cystic fibrosis patients, where thick layers 
of lung mucus and alginate surrounding mucoid bacterial cells can limit the diffusion of oxygen 
(Hassett, 1996; Worlitzsch et al, 2002; Williams et al, 2007; Brown, 1956).  
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Proteus: 
P. vulgaris, P. mirabilis and P. penneriare opportunistic human pathogens. Proteus 
includes pathogens for many human urinary tract infections. (Guentzel, 1996).  P. 
mirabilis causes wound and urinary tract infections. Most strains of P. mirabilis are sensitive 
to ampicillin and cephalosporins. P. vulgaris is not sensitive to these antibiotics. However, this 
organism is isolated least in the laboratory and usually only targets immunosuppressed 
individuals. P. vulgarisoccurs naturally in the intestines of humans and a wide variety of 
animals; also manure, soil and polluted waters. P. mirabilis, once attached to urinary tract it 
infects the kidney more commonly than E. coli. P. mirabilis are often found as free-living 
organisms in water and soil. Proteus species do not usually ferment lactose, but have shown to 
be capable lactose fermenters depending on the species in a triple sugar iron (TSI) test. Since it 
belongs to the family of Enterobacteriaceae, general behaviors  are applied on this genus: It 
isoxidase-negative, but catalase- and nitrase- positive. Specific tests includes 
positive urease (which is the fundamental test to differentiate Proteus from Salmonella) 
and phenylalanine deaminase tests. On the species level, indole is considered reliable, because it 
is positive for Proteus vulgaris but negative for Proteus mirabilis. 
 
 
 
 
 
 
 
 
 
Page | 6  
 
 
OBJECTIVES:- 
 
1. Isolation and pure culture of  Proteus  and Pseudomonas 
 
2. Biochemical characterization of pathogens. 
 
3. Resistance properties of Proteus and Pseudomonas toward various 
antibiotics.  
 
4. Determination of Minimum Inhibitory Concentration (MIC) of some 
important antibiotics toward  Proteus and Pseudomonas 
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3.1. Pseudomonas 
3.1.1. Disease 
 Pathogenic microbes are widespread in nature, inhabiting soil, water, plants, and animals 
(including humans). Pseudomonas aeruginosa has become an important agent of infection, 
especially in patients with compromised host defense mechanisms. It is the most common 
pathogen extracted from patients who have been hospitalized longer than 1 week. It is a frequent 
cause of nosocomial infections such as urinary tract infections (UTIs), pneumonia, and 
bacteremia. Pseudomonal infections are risky and can be life threatening. Pseudomonas 
aeruginosa is the opportunistic pathogen of humans. It is a major cause of hospital-acquired 
infections (nosocomial infections), and it is difficult to eradicate due to its resistance to most 
antimicrobial agents. There is probably no tissue that cannot become infected by Pseudomonas if 
the host defenses are weakened, and it is difficult to treat due to inherent and acquired resistance 
to antimicrobial agents. It is usually involved in urinary tract infections, soft tissue infections and 
pneumonia 
3.1.2. Pathophisiology 
P. aeruginosa is an opportunistic pathogen. It rarely causes disease in healthy persons. In most 
cases of infection, the integrity of a physical barrier to infection (eg. mucous membrane, skin) is 
lost or an underlying immune deficiency (eg, neutropenia, immunosuppression) is present. In 
addition to its pathogenicity, this bacterium has minimal nutritional requirements and can 
tolerate a wide variety of physical conditions. The pathogenesis of pseudomonas infections is 
multifactorial and complex. Pseudomonas species are both invasive and toxigenic. The 3 stages, 
are (1) bacterial attachment and colonization, (2) local infection, and (3) bloodstream 
dissemination and systemic disease. (Pollack, 2000). The importance of adherence and 
colonization is most evident when studied in the context of respiratory tract infection in patients 
with cystic fibrosis and in those that complicate mechanical ventilation. Production of 
extracellular proteases increases  the organism's virulence by assisting in bacterial adherence and 
invasion. As per the Centers for Disease Control and Prevention (CDC), the  overall prevalence 
of P aeruginosa infections in US hospitals is approximately 4 per 1000 discharges (0.4%).P 
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aeruginosa is also one of the most commonly isolated nosocomial pathogen, accounting for 
10.1% of all hospital-acquired infections. It is found on the skin of some healthy persons and has 
been isolated from the throat and stool of 5% and 3% of nonhospitalized patients, respectively. 
The gastrointestinal carriage rates among hospitalized patients increases to 20% within 72 hours 
of admission. 
Inhibits proliferation of human bone marrow progenitor cells: 
Pseudomonas aeruginosa exotoxin A, it is a potent inhibitor of eukaryotic protein synthesis, is 
produced in vivo at the time of  human infection. We tested that the hypothesis that exotoxin A 
may be responsible for the leukopenia which sometimes accompanies pseudomonas disease by 
examining the in vitro toxicity of exotoxin A for human bone marrow granulocyte-macrophage 
progenitor cells (colony-forming units in culture [CFU-c] in the soft agar cloning system. 
Colonization by freshly obtained marrow cells from five normal subjects was inhibited by 
exotoxin A in a concentration-dependent manner. The mean 50 and 100% inhibitory 
concentrations of toxin were 1.4 x 10(-10) and 1.4 x 10(-8) M, respectively, also significant 
inhibition was observed at a toxin concentration as low as 1.4 x 10(-13) M in two subjects. The 
inhibitory effect of exotoxin A on colony growth was specifically neutralized by antiserum to 
exotoxin A. Although mouse CFU-c were somewhat less sensitive to exotoxin A in vitro 
compared with human CFU-c, exotoxin A produced significant leukopenia in vivo in mice. 
These data gives a possible mechanism for the leukopenia which sometimes occurs in human 
pseudomonas disease. (Stuart and Pollack, 1982). Infectious morbidity may occur after 
endoscopy despite negative surveillance cultures. The process of routine endoscope cultures does 
not prevent device-linked infectious morbidity. (Fraser et al, 2004). 
3.1.3. Clinical Feature 
Clinical samples yield one or another of two smooth colony types. One type has a fried-egg 
appearance and is large, with flat edges, smooth and an elevated appearance. Another type, 
frequently found from respiratory and urinary tract secretions, has a mucoid appearance, is 
attributed to the production of alginate slime. The smooth and mucoid colonies are presumed to 
play a key  role in colonization and virulence. P. aeruginosa produce two types of soluble 
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pigments,the blue pigment pyocyanin and the fluorescent pigment pyoverdin. The former is 
produced abundantly in media of low-iron content and functions in iron metabolism in the 
bacterium. Pyocyanin (from "pyocyaneus") known as "blue pus", which is a characteristic of 
infections caused by Pseudomonas aeruginosa. 
 
3.1.4. PATHOGENESIS 
Outside the hospital most common infection caused by P.aeruginosa is suppurative otitis, which 
is chronic though not disabling. In the hospital, it may cause localised or generalised infections. 
Localized lesions are commonly infections of wounds, eye infections and urinary infections 
folowing catheterisation. P. aeruginosa is the most common and serious cause of infections in 
burns. It is also one of the agent s responsible for iatrogenic meningitis following lumbar 
puncture. It frequently causes post-tracheostomy pulmonary infection. Septicemia and 
endocarditis may occur in patients who are debilitated due to concomitant infection. Malignancy 
or immunosuppressive therapy. Ecthyma gangrenosum and many other types of skin lesions 
have been described occuring either alone or as part of generalised infection, mainly in patients 
with leukemia and other types of malignancy. Infection of the nail bed is not uncommon 
following axcessive exposure of hands to detergents and water. P. aeruginosa has been described 
as one of the agents responsible for infantile diarrhea and sepsis. Strains isolated from outbreaks 
of diarrhea may from a heat liable enterotoxin nad give a positive rabbit ileal loop reaction. P. 
aeruginosa has been reported to cause a self-limited febrile illness (Shanghai fever) resembling 
typhoid fever in some tropical areas. The pre-eminent role of P.aeruginosa in hospital infection 
is due to its resistance to common antibiotics and antiseptics, and its ability to establish itself 
widely in hospitals. Being an extremely adaptable organism it can survive and multiply even 
with minimal nutrients, if moisture is available. Equipment such as respirators and endoscopes, 
articles such as bed pans and medicines such as lotions, ointments and eye drops and even stocks 
of distilled water or plants and flowers may be frequently contaminated. P. aeruginosa is present 
on the skin of the axial and perineum in some persons. Fecal carriage is not common but may be 
frequent following oral antibiotics treatment or hospitalization. The mechanism of pathogenesis  
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is not clearly understood. Several toxic extracellular products have been identified in the culture 
filtrates, such as exotoxins A and S. exotoxins „A‟ acts as NADase, resembling the diarrheas 
toxin. Good antibody response to exotoxin A is considered a favourable sign in severe infections 
with P. aeruginosa. Other toxic products include protease, elastases, hemolysins and 
enterotoxins. The slime layer acts as a capsule in increasing virulence. 
3.1.5. Frequency of multidrug-resistance pseudomonas aeruginosa: 
The frequency of MDRPA infections is difficult to ascertain. Survival study evaluating in vitro 
susceptibility of commonly used antibiotics against clinical isolates of P. aeruginosa provides 
estimations of the rate of MDRPA infections. (Karlowsky et.al, 2003) However, there are a few 
limitations to consider. First, most of these surveillance studies did not use molecular techniques 
to eliminate clonal spread; thus, results may be an overestimation in outbreak situations. Second, 
these studies do not separates clinical infection from colonization. Finally, studies fails in 
standardization in definitions of multi drug resistance, which impedes direct comparisons of rates 
among studies. Because of these limitations, the trends in the isolation of MDRPA should be 
emphasized rather than actual rates reported. Studies meeting our definition of multi drug 
resistance reported increasing trends in MDRPA. From 1997-1999, the SENTRY Antimicrobial 
Surveillance Program published MDRPA rates of 8.2% in Latin America, 4.7% in Europe, 1.6% 
in Asia-Pacific, 1.2% in the United States, and 0.9% in Canada.(Gales, et al 2001). Among 1215 
isolates of P. aeruginosa collected from 1999-2000 in Japan, 3% were found to be multidrug-
resistant. (Kitahashi et al, 2001).The two recent surveillance studies reported increases in 
MDRPA in the United States. (Karlowsky et al, 2003) (Obritsch et al, 2004). From 1998-2001, 
the Surveillance Network noted that multidrug resistance increased from 5.5% to 7.0% of P. 
aeruginosa isolates in patients not in an intensive care unit and from 7.4% to 9.1% in patients in 
an intensive care unit. (Karlowsky et al, 2003). The Care Unit Surveillance Study reported a 
significant increase in MDRPA isolates from 4% in 1993 to 14% in 2002 (p<0.0001) (Obritsch 
et al, 2004). Rates of MDRPA in individual institutions are even higher than those reported in 
large surveillance studies. In a university hospital in Brazil, 10.2% of P. aeruginosa isolates 
(48/472) were reported as MDRPA in 1992 (Arruda et al, 1999). An institution in Greece 
indicated that 24.3% (25/103) of non-duplicate P. aeruginosa isolates from 1996-1997 were 
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resistant to almost all antimicrobials tested on it. (Sofianou and Tsakris, 1997) Among resistant 
strains of P. aeruginosa isolated from 1994-1998 in a French hospital, 24% (8/34) were reported 
as MDRPA. (Trouillet and Vuagnat, 2002). A university hospital in Italy reported a single case 
of MDRPA isolated in 1992; however, the rate increased significantly to 17% in 1999 (p=0.03). 
(Tacconelli et al, 2002). In the United States, a tertiary care teaching hospital reported similar 
increases in rates of MDRPA despite different definitions used. (D‟Agata, 2004). Among 
2344 P. aeruginosa isolates, an increase in MDRPA (resistance to ceftazidime, ciprofloxacin, 
and aminoglycosides) from 0.9% in 1994 to 5.6% in 2002 was identified. The same study 
evaluated multidrug resistance (to imipenem, ceftazidime, and ciprofloxacin) in 1989 P. 
aeruginosa isolates and reported an increase from 0.6% in 1994 to 4.7% in 2002. Recently, 
another academic medical center in the United States reported an increase in MDRPA from 0% 
(0/18) in 1998 to 32% (13/41) in 2002 (p=0.0025).( Jung R, Fish DN, Obritsch MD, et al, 2004). 
Therefore, rates of resistance are increasing on a global scale, as well as within specific 
institutions. Institution-specific surveillance of susceptibility of P. aeruginosa isolates to 
determination of rates of multidrug resistance and antipseudomonal agents are essential in 
guiding therapy in individual patients. 
3.1.6. Antibiotic Resistance 
Pseudomonas aeruginosa is a very relevant opportunistic pathogen. One of the most worrisome 
characteristics of P.aeruginosa is its low antibiotic susceptibility. This low susceptibility is count 
to a concerted action of multidrug efflux pumps with chromosomally-encoded antibiotic 
resistance genes (e.g., mexAB, mexXY etc.) and the low permeability of the bacterial cellular 
envelopes. In addition to this intrinsic resistance, P. aeruginosa frequently develops acquired 
resistance either by mutation in chromosomally-encoded genes or by the horizontal gene 
transfers of antibiotic resistance determinants. Development of multidrug 
resistance by P.aeruginosa isolates requires several different genetic events such as acquisition 
of different mutations and/or horizontal transfer of antibiotic resistance genes. Hypermutation 
helps the selection of mutation-driven antibiotic resistance in P. aeruginosa strains producing 
chronic infections, but the clustering of several different antibiotic resistance genes 
in integrons favors the concerted acquisition of antibiotic resistance determinants. Some recent 
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studies have concluded that phenotypic resistance associated to biofilm formation or to the 
emergence of small-colony variants may be important in the response of P. 
aeruginosa populations to antibiotics treatment (Cornelis, 2008).  
3.2. Proteus  
Proteus mirabilis is a Gram-negative, facultativelyanaerobic, rod shaped bacterium. It 
shows swarming motility, and urease activity. P. mirabilis causes 90% of all 'Proteus' infections 
in humans. Proteus species are of the Enterobacteriaceae family of gram-negative 
bacilli. Proteus organisms are implicated as serious reason of infections in humans, along 
with Escherichia, Klebsiella, Enterobacter, and Serratiaspecies. Proteus species are mostly 
found in the human intestinal tract as part of normal human intestinal flora, along 
with Escherichia coli  and Klebsiella species, of which E coli is the predominant 
resident. Proteus is also found in multiple environmental habitats hospitals. In hospital settings, 
it is not unusual for gram-negative bacillus to colonize both the skin and oral mucosa of both 
patients and hospital personnel. Infection primarily occurs from these reservoirs. 
However, Proteus species are not the most common cause of nosocomial infections. Proteus 
mirabilis causes 90% of Proteus infections also can be considered a community-acquired 
infection. Proteus vulgaris and Proteus penneri are isolated from individuals easily in long-term 
care facilities and hospitals and from patients with underlying diseases or compromised immune 
systems. Patients with recurrent infections, with structural abnormalities of the urinary tract, 
those who have had urethral instrumentation, and those whose infections were acquired in the 
hospital have an increased frequency of infection caused by Proteus.  
3.2.1. Pathophysiology: 
Proteus species having an extracytoplasmic outer membrane, a feature shared with other gram-
negative bacteria. In addition, the outer membrane contains a lipid bilayer, lipoproteins, 
polysaccharides, and lipopolysaccharides. Infection depends on the interaction between the 
infecting organism and the host defense mechanisms. Various components of the membrane 
interplay with the host to determine virulence. Inoculum size is important and has a positive 
correlation with the risk of infection. Certain virulence factors have been identified in bacteria. 
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The first step in the infectious process is adherence of the microbe to host tissue. Fimbriae 
facilitate adherence and thus enhance the capacity of the organism to produce disease. E coli, P 
mirabilis, and other gram-negative bacteria contain pili, which are tiny projections on the surface 
of the bacterium. Specific chemicals located on the tips of pili enable organisms to attach to 
selected host tissue sites (eg, urinary tract endothelium). The presence of these fimbriae has been 
demonstrated to be important for the attachment of P mirabilis to host tissue. The adhesion 
of Proteus species to uroepithelial cells initiates several events in the mucosal endothelial cells, 
including secretion of interleukin 6 and interleukin 8. Proteus organisms also induce epithelial 
cell desquamation. Bacterial production of urease has also been shown to increase the risk of 
pyelonephritis in experimental animals. Urease production, together with the presence of 
bacterial motility and fimbriae, may favor the production of upper urinary tract infections (UTIs) 
by organisms such as Proteus. Proteus and Pseudomonas species are the microorganisms most 
commonly responsible for gram-negative bacteremia. When these pathogens enters the 
bloodstream, endotoxin, a component of gram-negative bacteria cell walls, apparently triggers a 
cascade of host inflammatory responses and leads to major detrimental effects. 
As Proteus and Pseudomonas both are gram-negative, they can cause gram-negative endotoxin-
induced sepsis, resulting in systemic inflammatory response syndrome (SIRS), which carries a 
mortality rate of 20%-50%. Although other organisms can trigger a similar response, it is useful 
to consider gram-negative bacteremia as a distinct entity because of its characteristic 
epidemiology, pathogenesis, pathophysiology, and treatment. The presence of the sepsis 
syndrome associated with a UTI should raise the possibility of urinary tract obstruction. This is 
especially true of patients who reside in long-term care facilities, who have long-term indwelling 
urethral catheters, or who have a known history of urethral anatomic abnormalities. The ability 
of Proteus organisms to produce urease and to alkalinize the urine by hydrolyzing urea to 
ammonia makes it effective in producing an environment in which it can survive. This leads to 
precipitation of organic and inorganic compounds, which leads to struvite stone formation. 
Struvite stones are composed of a combination of magnesium ammonium phosphate (struvite) 
and calcium carbonate-apatite. Struvite stone formation can be sustained only when ammonia 
production is increased and the urine pH is elevated to decrease the solubility of phosphate. Both 
of these requirements can occur only when urine is infected with a urease-producing organism 
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such as Proteus. Urease metabolizes urea into ammonia and carbon dioxide: Urea → 2NH3 + 
CO2. The ammonia/ammonium buffer pair has a pK of 9.0, resulting in the combination of 
highly alkaline urine rich in ammonia. Symptoms attributable to struvite stones are uncommon. 
More often, women present with UTI, flank pain, or hematuria and are found to have a 
persistently alkaline urine pH (>7.0). The genitourinary tract is the place of disease responsible 
for gram-negative bacteremia in approximately 35% of patients. In previously healthy 
outpatients, E coli is by far the most often implicated cause of UTIs. In contrast, individuals with 
multiple prior infections of UTI, multiple antibiotic treatments, urinary tract obstruction, or 
infection developing after instrumentation frequently become infected with  Proteus bacteria or 
other bacteria such as Enterobacter, Klebsiella, Serratia, and Acinetobacter. Bacteriuria occurs in 
10%-15% of hospitalized patients with indwelling catheters. The risk of infection is 3%-5% per 
day of catheterization. 
3.2.2. Multidrug resistance proteus mirabilis: 
 Isolates from Poland beach several blaCMYs (blaCMY-4, -12,
 
-14, -15, -38 and a new blaCMY-45), while 
isolates from Italy
 
and Greece harbored blaCMY-16 only. Earlier collected with blaCMY-4
 
or -12, 
recovered in France from Greek and Algerian patients,
 
were also studied. All isolates showed 
striking similarities.
 
. Moreover, modules were
 
inserted into the same chromosomal site, within 
the pepQgene.
 
Since ColE1 plasmids carrying ISEcp1 with similar C. freundii
  
DNA fragments 
(Tn6114) had been studied earlier, it is likely
 
that a similar molecule had mediated at some stage 
this DNA
 
transfer between C. freundii and P. mirabilis. Isolates with blaCMY-12, -15 and -38 genes 
second
 
blaCMY copy within a shorter ISEcp1 module (Tn6113), always
 
inserted downstream of 
the ppiD gene. Sequence analysis of all
 
mobile blaCMY-2-like genes shows that those integrated 
in
 
the P. mirabilis chromosome form a distinct cluster that may
 
have formed by the stepwise 
accumulation of mutations. All
 
these observations, coupled to strain typing data, suggest 
that
 
the blaCMY genes studied here may have originated from a single
 
ISEcp1-mediated 
mobilization-transfer-integration process, followed
 
by spread and evolution of a P. 
mirabilis clone over time and
 
a large geographic area. (D‟Andrea et al, 2011). 
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3.3. Antibiotics and their mechanism of action: 
3.3.1. Tetracycline 
Tetracyclines were discovered in the 1940s (Fig 1) and exhibited activity against a wide 
range of microorganisms including gram-positive
 
and gram-negative bacteria, chlamydiae, 
mycoplasmas, rickettsiae,
 
and protozoan parasites. These are inexpensive antibiotics, which
 
have 
been used extensively in the prophlylaxis and therapy of
 
human and animal infections and also at 
subtherapeutic levels
 
in animal feed as growth promoters. The initial tetracycline-
resistant
 
bacterium, Shigella dysenteriae, was isolated in 1953. Tetracycline
 
resistance now found 
in an increasing number of pathogenic, opportunistic,
 
and commensal bacteria. The presence of 
tetracycline-resistant
 
pathogens limits the use of these antibiotics in treatment of 
disease.
 
Tetracycline resistance is often due to the acquisition of transgenes, which code for 
energy-dependent efflux of tetracyclines
 
or for a protein that protects bacterial ribosomes from 
the action
 
of tetracyclines. Many of these genes are linked with mobile
 
plasmids or transposons 
and can be distinguished from each other
 
using molecular methods including DNA-DNA 
hybridization with oligonucleotide
 
probes and DNA sequencing. A little number of pathogens 
acquire
 
resistance by mutations, which alter the permeability of the outer
 
membrane porins 
and/or lipopolysaccharides in the outer membrane,
 
change the regulation of innate efflux 
systems, or alter the 16S
 
rRNA (Fig 2). New tetracycline derivatives are beingstudied, 
although
 
their role in treatment is not clear. Changing the use of tetracycline
 
in human and 
animal health as well as in food production is needed
 
if we are to continue to use this class of 
broad-spectrum antimicrobials
 
through the present
 
century (Ian et al, 2011). 
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Fig 1: Tetracyclin chemical struture 
 
       
      Fig 2: Tetracycline mode of action 
 
3.3.2.  Vancomycin: Vancomycin was first isolated (Fig 3) in 1953 by Edmund 
Kornfeld (working at Eli Lilly) from a soil sample collected from the interior jungles 
of Borneo by a missionary. (Shnayerson et al, 2003). The organism that produced it 
was initially named Amycolatopsis orientalis. (Levine et al 2006). The real use for 
vancomycin was for the treatment of penicillin-resistant strains. (Moellering et al, 
2006) (Levine et al, (2006). 
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                                Fig 3: Vancomycin chemical structure 
Mechanism of Action: Vancomycin is an antibiotic produced by streptomyces orientalis. It is a 
complex chemical entity consisting of amino acids and sugars. Vancomycin inhibits 
peptidoglycan synthesis by binding the D-alanyl-D-alanine group on the peptide side chain of 
one of the membrane-bound intermediates (Fig 4). Vancomycin affects by inhibiting cell 
wall synthesis in Gram-positive bacteria. Due to the different mechanism by which Gram-
negative bacteria form their cell walls and the various factors related to entering the outer 
membrane of Gram-negative organisms, vancomycin is not active against Gram-negative 
bacteria (except some non-gonococcal species of Neisseria). To specific, vancomycin prevents 
joining of N-acetylmuramic acid (NAM) and N-acetylglucosamine (NAG) peptide subunits into 
the cell wall peptidoglycan matrix; which forms the major structural component of Gram-
positive cell walls. The large hydrophilic molecule are able to formation of hydrogen 
bond interactions within the terminal D-alanyl-D-alanine moieties of the NAM/NAG-peptides. 
Under normal circumstances, it is a five-point interaction. This attachment of vancomycin to the 
D-Ala-D-Ala prevents the incorporation of the NAM/NAG-peptide subunits into the 
peptidoglycan matrix. 
                                      
                                   Fig 4: mechanism of action of vancomycin 
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3.3.3. Ciprofloxacin 
Ciprofloxacin is a synthetic chemotherapeutic antibiotic (Fig 5) of the fluroquinolone drug class 
(Nelson et al, 2007), (Kawahara et al, 1998). It is a secondgeneration fluoroquinolone 
antibacterial. It stops bacterial infections by interfering with the enzymes that cause DNA to 
rewind after being copied,which stops synthesis of DNA and protein. 
                     
                                Fig 5: Ciprofloxacin chemical structure 
 
Mechanism of action: Ciprofloxacin is one of the broad-spectrum antibiotic active against 
both Gram-positive and Gram-negativebacteria. It works by inhibiting DNA gyrase, 
topoisomerase IV and a type II topoisomerase (Drlica et al, 1997) enzymes necessary to separate 
bacterial DNA, thereby inhibiting cell division. This mechanism can also affect mammalian cell 
replication. In particular, some compounds of this drug family (for example those that contain 
the C-8 fluorine) (Robinson et al, 1992) display high activity not only against bacterial 
topoisomerases but also against eukaryotic topoisomerases and are toxic to cultured mammalian 
cells and in vivo tumor models. (Sissi and Palumbo, 2003).  Although quinolones are very much 
toxic to mammalian cells in culture, its mechanism of cytotoxic action is not known. Quinolone-
induced DNA damage was first reported in 1986. (Hussy et al, 1986). Recent studies have shown 
a correlation between mammalian cell cytotoxicity of the quinolones and the induction 
of micronuclei. (Forsgren et al, 1987), (Gootz et al, 1990) As such, some fluoroquinolones also 
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cause injury to the genes of eukaryotic cells. (Elsea et.al, 1992), (Suto et a,l 1992), (Enzmann et 
al, 1999), There continues to be debate as to whether or not this DNA damage is to be considered 
one of the mechanisms of action concerning the severe adverse reactions experienced by some 
patients following fluoroquinolone therapy. (Sissi and Palumbo 2003), (Yaseen et al, 2003). 
 
3.3.4.  Amoxicillin 
Amoxycillin is a moderate-spectrum, bacteriolytic, β-lactam antibiotic (Fig 6)  used to 
treat bacterial infections caused by susceptible microorganisms. Usually the drug of choice in the 
class because it is comparatively better  absorbed, following oral administration, than other β-
lactam antibiotics. Amoxicillin is the most common antibiotics prescribed for children. 
Amoxicillin is sensitive to degradation by β-lactamase-producing bacteria, which are resistant to 
a broad spectrum of β-lactam antibiotics, such as penicillin. For this cause, it is often mixed with 
clavulanic acid, a β-lactamase inhibitor, and marketed under one name. This upgiven 
effectiveness by reducing its susceptibility to β-lactamase resistance. 
                       
                  Fig 6: Amoxicillin chemical structure 
 
Mechanism of action: This drug works by preventing the formation of bacterial cell walls. It 
prevents cross-linkage among the linear peptidoglycan polymer chains that make up a major 
component of the cell walls of both Gram-positive and Gram-negative bacteria. It has 
Page | 20  
 
two ionizable groups present in between the physiological range (the amino group in alpha-
position to the amide carbonyl group and the carboxyl group). 
3.3.5.  Chloramphenicol 
Chloramphenicol is a bacteriostatic antimicrobial (Fig 7). It is a most common broad-spectrum 
antibiotic, alongside the tetracycline. Chloramphenicol is effective against a variety of Gram-
negative and Gram-positivebacteria, including most anaerobic organisms. It prevents the peptidyl 
bond formation between the amino acids of growing polypeptide chain. (Fig 8). 
 
                              
 
                          Fig 7: chloramphenicol chemical structure 
Mechanism of action: 
                      
                     Fig 8: mode of action of chloramphenicol 
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4.1. COLLECTION OF SAMPLE 
Pathogenic sample was collected from the hospital, Ispat General Hospital, Rourkela. 
 
4.2. ISOLATION OF PURE CULTURE 
Pure cultures of the pathogens were isolated by using nutrient agar plate. From the pathogenic 
bacteria vial by streaking on the nutrient agar medium pure isolated colonies of pathogenic 
bacteria can be obtained. 
Further expements such as antibiotic susceptibility test and minimum inhibitory concentration 
analysis was done by using Muller-Hinton agar and Muller-Hinton broth respectively. 
4.3. BIOCHEMICAL IDENTIFICATION TESTS 
Indole produdtion test: The indole test is a biochemical test tested on bacterial pathogenic 
species to determine the ability of the organism to split indole from the amino acid tryptophan. 
This division is produced by a chain of a number of different intracellular enzymes, a system 
generally referred to as “tryptophanase”. 
Principle 
Indole is produced by a reductive deamination from tryptophan via the intermediate molecule 
indole pyruvic acid. Tryptophanase enhances the deamination reaction, during which the amine 
(NH2) group of the tryptophan molecule is removed. Final products of the reaction are pyruvic 
acid, indole, ammonia (NH3) and energy. The indole produced during the reaction is detected by 
the addition of Kovac‟s reagent (dimethylaminobenzaldehyde) which produces a cherry-red 
reagent layer. A positive result was  the presence of a red or red color in the surface alcohol layer 
of the broth. A negative result appears yellow. Variable result may also occur, showing an 
orange color as a result. 
Methyl red test: The Methyl-Red test tests for the importance to perform mixed-acid 
fermentation.MR-VP broth contain glucose, peptone, and a phosphate buffer. Organisms that 
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perform mixed-acid fermentation produce sufficient acid to jumpover the buffering capacity of 
the broth, so a decrease in pH results. Organisms that perform other kinds of fermentation cannot 
crossover the buffering capacity of the broth. After incubation, the pH indicator Methyl Red was 
added to the broth. Methyl Red shows red at pH below 4.4 (this may  be a positive result) and 
yellow at pH above 6.0. An orange color indicates an intermediate pH and may be a 
negative result.  
4.4 McFarland standard: 
McFarland standards are extensively used as turbidity standards for the preparation of 
suspensions of microorganisms. The McFarland 0.5 standard has various application in the 
preparation of bacterial inocula for performing antimicrobial susceptibility testing. One of the 
earliest uses of turbidity for the enumeration of bacterial populations was in the preparation of 
vaccines (Lorian, 1986). In 1907 McFarland developed a number of barium sulfate solutions to 
approximate the numbers of bacteria in solutions of equal turbidity, as determined by plate 
counts (McFarland, 1907) (Forbes et al, 1998). The capability of susceptibility testing requires 
the use of standard inocula. The McFarland 0.5 standard was used for the preparation of inocula 
in standardized agar dilution, broth macro- and microdilution, disc diffusion and anaerobic 
organism susceptibility test procedures. 
 
4.4. PRINCIPLES OF THE PROCEDURE 
Turbidity standards are prepared by adding homogenously chemicals that precipitate to form a 
solution of reproducible turbidity.3 McFarland standards are prepared by adding sulfuric acid to 
an aqueous solution of barium chloride, which results in the formation of a suspended barium 
sulfate precipitate. The McFarland 0.5 standard corresponds approximately to an homogeneous 
Escherichia coli suspension of 1.5 x 108 cells per mL. (Forbes et al, 1998). 
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REAGENTS: 
McFarland Turbidity Standard No. 0.5 
Approximate Formula Per 100 mL Purified Water 
Sulfuric Acid, 0.18 M . . . . . . . . . . . . . . . . . . . . . . . . . . 99.5 mL 
Barium Chloride, 0.048 M . . . . . . . . . . . . . . . . . . . . . . . 0.5 mL 
 
Vigorous agitation using a mechanical vortex mixer, density was checked for the turbidity 
standard by determining the absorbance using a spectrophotometer with a 1-cm light path and 
matched cuvette. The absorbance at 625 nm should be 0.08 to 0.10. 
 
 
USE: 
Use of the McFarland 0.5 standard will enable the preparation of standardized inocula for use in 
the performance of standardized antimicrobial susceptibility testing procedures. 
 
 
4.5. Antimicrobial susceptibility test: 
Disc diffusion method  
Modified Kirby-Bauer disk diffusion method was used to test the susceptibility of the Proteus 
and pseudomonas isolates to different antimicrobial agents: ampicillin (10 μg), tetracycline (30 
μg), chloramphenicol (30 μg), vancomycin (30 μg), kanamycin (30 μg), and ciprofloxacin (30 
μg), The inocula were prepared by growing the various Proteus species on separate agar plates 
and colonies from the plate were transferred with inoculating loop into 3 ml of normal saline in a 
test tube. The density of these suspensions was adjusted to 0.5 McFarland standards. The surface 
of Muller-Hinton agar plate was evenly inoculated with the organisms using a sterile swab. The 
swab was dipped into the suspension and pressed against the side of the test tube to remove 
excess fluid. The wet swab was then used to inoculate the Muller-Hinton agar, evenly streaked 
across the surface. By means of Disc Dispenser the antibiotic discs were applied to the surface of 
the inoculated agar and the plates were incubated overnight at 37 
0
C. The diameter of zone of 
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inhibition was observed and measured and compared to the chart provided by National 
Committee for Clinical Laboratory Standards (NCCLS). 
 
4.6. PROCEDURE: 
                             Muller-Hinton Agar was prepared. 
 
From the standardized inoculums prepared by using 0.5 McFarland solutions was then Spreaded 
over the media surface using a clean sterilized cotton swab. 
 
Different antibiotic disks were placed in each plate with proper spacing using a sterile forcep. 
 
 
Now the plates were kept for incubation at 37
0
C for 24 hour for proper growth. 
 
 
Antibiotics to which organisms are sensitive, formed clear zone around it, and to which       
organisms are resistance, they do not form any zone of inhibition around it. Those that are 
intermediate, forms a little zone of inhibition. 
 
 
 
Diameter of the zone was measured ,compared with the standard zone diameter given in the 
protocol chart it can be determine that whether the strain is resistance or intermediate or 
susceptible toward the antibiotic. 
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4.7. PREPARATION OF SERIALLY DILUTED ANTIMICROBIAL 
AGENT: 
 
The antimicrobial agents are diluted to a number of times with ratio 1:1. The concentration of 
antibiotic in the solution is in microgram/mL. 
The quantity of antimicrobial agent to be taken for the preparation of a known concentration of 
antibiotic solution was carried out by using the following formula. 
 
                                                          
                                                          VOLUME (mL) * Conc. (µg/mL) 
                           WEIGHT (mg) = --------------------------------------------- 
                                                                 POTENCY (µg/mg) 
 
Biochemical identification test: 
Pseudomonas: Biochemical analysis shows that this strain of  pseudomonas is gram negative, 
aerobic rod, the species identified in the biochemical identification (Fig 9) analysis is 
pseudomonas aeruginosa.. 
                                             
                                        
                              Fig -9 Biochemical test result for Pseudomonas 
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Proteus: Biochemical analysis shows (Fig 10) that the strain of proteus identified is proteus 
mirabilis. 
                                   
                              Fig-10 Biochemical test result for Proteus 
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Table 1: Enterobacteriaceae Identification test 
 
 
 
Sl.No.                Test proteus Pseudomonas 
1 ONPG - - 
2 Lysine utilization - + 
3 Ornithine utilization - + 
4 Urease - - 
5 Phenylalanine 
deamination 
- + 
6 Nitrate reduction + + 
7 H2S production - + 
8 Citrate utilization + + 
9 Voges proskauer‟s + - 
10 Methyl red + - 
11 Indole - + 
12 Malonate utilization - + 
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Sl.No. Test proteus pseudomonas 
13 Esculin hydrolysis + + 
14 Arabinose - + 
15 Xylose - + 
16 Adonitol - - 
17 Rhamnose - - 
18 Cellobiose + - 
19 Melibiose - - 
20 Saccharose + - 
21 Raffinose - - 
22 Trehalose + + 
23 Glucose + + 
24 Lactose + - 
25 Oxidase + - 
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Table 2: Carbohydrate Utilization Test 
 Sl NO. TEST Proteus  pseudomonas 
PART A           
1 Lactose - - 
2 Xylose - + 
3 Maltose + - 
4 Fructose + - 
5 Dextrose + - 
6 Galactose + + 
7 Raffinose - - 
8 Trehalose + - 
9 Melibiose - - 
10 Sucrose + - 
11 L- arabinose - + 
12 Mannose + + 
PART B    
13 Inulin + - 
14 Sodium gluconate + - 
15 Glycerol - - 
16 Salicin + - 
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17 Dulcitol - - 
18 Inositol - - 
19 Sorbitol + - 
20 Mannitol + - 
21 Adonitol - - 
22 Arabitol - - 
23 Erythritol - - 
24 α – methyl –D-glucoside - - 
PART C    
25 Rhamnose - - 
26 Cellobiose + - 
27 Melezitose + - 
28 α –methyl-D-mannoside - - 
29 Xylitol - + 
30 ONPG - - 
31 Esculin hydrolysis + + 
32 D-Arabinose - + 
33 Citrate utilization - + 
34 Malonate utilization - + 
35 Sorbose - - 
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Table -3: Antibiotic disk diffusion test: 
 
As pseudomonas is resistance to the entire antibiotic hence no zone of inhibition was formed 
(Fig 11). 
 
 
                             Fig-11 Pseudomonas antibiotic disc diffusion test 
 
 
                                                        
 
 
Tetracycline 
(30 mcg) 
 
Vancomycin 
( 30 mcg) 
 
Ciprofloxacin 
(30 mcg) 
 
Amoxicillin 
(30 mcg) 
 
Chloramphenicol 
(30 mcg) 
 
Kanamycin 
(30 mcg) 
pseudomonas Resistance Resistance Resistance Resistance Resistance Resistance 
Proteus Resistance Sensitive Resistance Sensitive Resistance Resistance 
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Very small zone of inhibition was formed around amoxicillin and vancomycin, but no zone 
formation around other antibiotics (Fig 12). 
 
                                 
                             Fig-12 proteus antibiotic disc diffusion test 
 
1. Pseudomonas shows resistance towards most antibiotics. 
2. Proteus shows sensitive towards some antibiotic like vancomycin and amoxicillin. 
3. Vancomycin and amoxilin are least effective toward these microorganisms. 
4. Tetracycline, ciprofloxacin, chloramphenicol and kanamycin are most effective toward 
these microorganisms. 
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Table 4:  Antibiogram of disk diffusion technique 
      organism                           antibiogram 
 
    Pseudomonas 
 
                T
R 
V
R 
Cf
R 
Am
R 
C
R 
K
R 
 
       proteus 
 
                T
R
 V
S
 Cf
R
 Am
S
 C
R
 K
R 
 
 
MIC RESULT: Concentration of antibiotic solution=µg/mL 
MIC is the minimum concentration of antibiotic at which the bacteria shows a 
remarkable inhibition. 
Table -5:  Minimum inhibitory concentration 
    Vancomycin       Penicillin Chloramphenicol    Amoxicillin 
pseudomonas             32             8             16      Resistance 
proteus             16             4        Sensitive       Sensitive 
 
1. Pseudomonas is resistance toward amoxicillin. 
2. Proteus is sensitive toward chloramphenicol and amoxicillin. 
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DISCUSSION: 
Mode of resistance to antimicrobials used for the treat infectious disease has been known since 
before antibiotics were introduced into routine clinical usage (Abraham and Chain 1940). 
Imprudent and often regular administration of antimicrobials has, however, compounded the 
problem by enriching for resistant bacteria populations at the expense of sensitive ones (Lerner 
1998; Hellinger 2000; Livermore 2000). With all too increasing frequency human pathogens 
proteus and pseudomonas displaying resistance to multiple antimicrobials, and the attendant 
challenge of treating infections with an ever-dwindling number of effective therapeutic agents. 
Pathogen shows resistance to antimicrobial agents as they are mutating their genome or 
acquiring some resistance mechanism. Administration of antibiotics for prolonged period helps 
in increasing the resistance mechanism of the pathogens. Multi drug resistance Pseudomonas 
aeruginosa increases its resistance capacity and potency to a higher extent. So some potential 
drug should be made for the treatment of P.aeruginosa infections. Similarly: The Proteus species 
isolated were found to have high antimicrobial resistance against tetracycline, chloramphenicol. 
Proteus also acquiring resistance to multiple drugs.  It is susceptible to some antibiotics like 
chloramphenicol, vancomycin, and amoxicillin. Regular drug administration to these strains 
would acquire multi-drug resistance property. Pseudomonas aeruginosa has became increasingly 
recognized as an emerging opportunistic pathogen of clinical relevance. Several epidemiological 
studies shows its occurrence as a nosocomial pathogen and indicate that antibiotic resistance is 
increasing in clinical isolates Pseudomonas shows resistance toward most antibiotics. The 
minimum inhibitory concentration of antibiotics toward pseudomonas is very high. 
FUTURE PROSPECTS 
In light of current problems with multiple antibiotic resistances in clinical strains and the 
potential for increasing resistance to antibiotic whose use is increasing in the community, it is 
clear that prudent use of available and as yet effective antimicrobials is called for. Nonetheless, 
resistance is a common theme in infection and one that is unlikely to disappear soon. For this 
reason, the targeting of resistance mechanisms themselves was gaining ability(Wright 2000; 
Poole 2001c), with more generalized resistance mechanisms such as membrane impermeability 
and multidrug efﬂux possibly favoured targets. The ﬁrst inhibitors of the broadly speciﬁc 
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multidrug efﬂux systems of Ps. aeruginosa have recently been reported in the literature (Renau 
et al. 1999; Lomovskaya et al. 2001). Effective at overcoming existing resistance to, e.g. 
ﬂuoroquinolones, these agents are also effective at preventing the emergence of ﬂuoroquinolone 
resistance in the ﬁrst place (Lomovskaya et al. 2001). They are likely,to be highly effective at 
compromising intrinsic and acquired biocide (i.e. triclosan) resistance in this organism as well as 
antibiotic and biocide resistance in organisms expressing homologous multidrug efﬂux systems 
(Blais et al. 1999). Inhibitors of the NorA multidrug transporter of Staph. aureus have also been 
reported (Schmitz et al. 1998; Aeschlimann et al. 1999; Markham et al. 1999; Guz et al.2001) 
where they are effective at enhancing ﬂuoroquinolone susceptibility (Schmitz et al. 1998; 
Aeschlimann et al. 1999; Markham et al. 1999) and preventing emergence of ﬂuoroquinolone 
resistance in vitro (Markham and Neyfakh 1996). Similarly, enhancement of antimicrobial 
susceptibility using agents that permeabilize, e.g. the outer membrane has shown some 
challenging promise, for speciﬁc antimicrobials (Ayres et al. 1998; Savage 2001; Poole 2001). 
Finally, owing to the prevalence of the bioﬁlm mode of bacterial growth in vivo and its 
importance vis-a`-vis antibiotic and biocide insusceptibility, strategies aimed at interfering with 
bioﬁlm formation/ function are also likely to be useful in countering clinical episodes of 
antibiotic and biocide resistance. Natural susceptibility in populations of disease-causing bacteria 
through the prudent use of current and future antimicrobials. Compounds that interfere with 
bacterial cell signaling processes necessary for bioﬁlm formation have now been identiﬁed 
(Maneﬁeld et al. 1999; Rice et al. 1999; Borchardt et al. 2001) and could be useful in blocking 
bioﬁlm formation or maintenance. Chemical (Armstrong et al. 2000) and electromagnetic 
(Blenkinsopp et al. 1992; McLeod et al. 1999) approaches to bioﬁlm disruption have also been 
reported. Still, the best hope of controlling infectious diseases is and will continue to be 
maintaining susceptibility in populations of disease-causing bacteria through the prudent use of 
current and future antimicrobials. 
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APPENDIX I 
Nutrient agar  
Ingredients                   Gms / Litre 
Peptic digest of animal tissue 5.000 
Sodium chloride 5.000 
Beef extract 1.500 
Yeast extract 1.500 
Agar 15.000 
Final pH ( at 25°C) 7.4±0.2 
Muller-Hinton agar 
For 1 liter of medium:  
- Acid hydrolysate of casein .............................................................17.5 g  
- Beef infusion ....................................................................................2.0 g  
- Soluble starch ..................................................................................1.5 g  
- Bacteriological agar .......................................................................17.0 g  
pH of the ready-to-use medium at 25°C : 7.3 ± 0.2 
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APPENDIX II 
 
0.5 McFarland standard 
Sulphuric Acid ,1%                         995.00 ml 
Barium Chloride, 1%                      5.00 
 
Kovac’s reagent 
 p-Dimethylaminobenzaldehyde  7 4.8%  
Isoamyl Alcohol      4.8%  
Hydrochloric Acid   23.8% 
 
TDA reagent 
Ferric chloride 10g/100ml (in distilled water) 
Baritt reagent 
Methyl reagent 
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